Status:
NOT_YET_RECRUITING
Hyperlipoproteinemia A as a Marker of Cardiovascular Risk in Patients With Stage 4 Chronic Kidney Disease
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
CKD
Cardiovascular Diseases
Eligibility:
All Genders
18-80 years
Brief Summary
The blood level of lipoprotein A (Lp(a)) is linked to mutations in gene 6 and is associated with atherothrombotic risk and clinical manifestations such as myocardial infarction, ischemic stroke, and a...
Eligibility Criteria
Inclusion
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- Patient being followed at the Nîmes University Hospital for stage 4 chronic kidney disease without replacement therapy
- Patient available for follow-up at 18 months
Exclusion
- The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Familial hypercholesterolemia
- Morbid obesity (BMI \> 40 kg/m2).
- Persons deprived of their liberty by a judicial or administrative decision, persons receiving psychiatric care, and persons admitted to a health or social care facility for purposes other than research (Article L1121-6 of the French Public Health Code)
Key Trial Info
Start Date :
January 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07141628
Start Date
January 1 2026
End Date
September 1 2027
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France, 30029